Dokumenti

JSC Olainfarm Concludes Year 2017 With The Highest Turnover Of The Company's History And Expands Globally

Emitents

Olainfarm, AS (213800WCG52W62ENOP27)

Veids

1.1 Gada finanšu pārskati un revīzijas ziņojumi

Valoda

Statuss

Publicēts

Versija

Aktuālā (1)

Datums

2018-04-27 17:16:07

Versijas komentārs

Teksts

April 27, 2018

JSC Olainfarm Concludes Year 2017 With The Highest Turnover Of The Company's History And Expands Globally Audited consolidated financial statement of JSC Olainfarm for 2017 shows that the sales of the Group exceeded 122 million euros. This represents an increase by 10% compared to sales of 2016 and is by far the largest turnover in the company's history. The profit of Olainfarm Group last year reached 10.8 million euros. The company has successfully expanded its export by adding new markets and selling its products now to 66 countries worldwide. Russia, Latvia, Ukraine and Belarus remain the largest product markets.

Together with the consolidated financial data, JSC Olainfarm this year also submitted for the first time a non-financial report, which informs about the company's environmental and social responsibility, quality management and corporate governance practice. The non-financial report is based on the Nasdaq ESG guidelines for the Nordic and Baltic markets.

Turnover growth was mostly ensured by the increase in sales of subsidiaries, as the sale of the Parent company in 2017 actually remained at the level of year 2016, increasing by a half percentage point. The company has added 4 new markets to its product geography in 2017 and commenced sales in Argentina, Colombia, Hong Kong and Romania. In total, the Group exported its products to more than 60 countries worldwide. In 2017, the share of Russia in total sales increased from 34% to 35%, while due to the changing economic situation, the sales in Ukraine decreased from 13% to 10%. Decline in sales volumes has been also experienced in Great Britain, while significant growth by 103% was reached in Germany, the Netherlands (+ 57%) and Belarus (+ 21%).

In 2017 JSC Olainfarm has successfully completed the registration of its products in Latvia, Kyrgyzstan, Armenia, Azerbaijan and Moldova. Registration processes are still ongoing in Nepal, Armenia, Turkey, Myanmar, Cameroon and Vietnam.

The best sold products of the Parent company in 2017 were CNS medicines Neiromidin, Noofen and Adaptol, antibacterial preparations of Furamag and Furasol, antiarrhythmic medicine Etacizin, antituberculosis products PASS Sodium salt and antiallergic medicine Fenkarol.

A slight change over the year has occurred in the proportion of the most sold products. The proportion of soluble Furagin products has increased from 13% to 15%, the share of Etacizin has increased from 8% to 10%, while the proportion of PASS Sodium Salt has decreased from 8% to 5%. The list of 10 the most-selling pharmaceutical products has remained unchanged.

The Annual meeting of shareholders of JSC Olainfarm on June 1, 2017 approved operating plan of the Group for 2017. According to it, sales of the Group in 2017 were planned to be 127 million euros, the parent company's turnover was expected to reach 96 million euros, while net profit - 15.5 million euros. Taking into account the unsatisfactory profitability in the third quarter, the company's board reviewed its 2017 earnings outlook, stating that the expected 2017 consolidated and non-consolidated profit is 9 million euros with potential to increase it to 10 million euros. According to the financial results of the consolidated financial statements, the Group's annual sales plan is executed at 96%, while the revised Group's annual profit plan is overflowing by 8%. The Parent company’s sales target is executed at 95%, while the profit plan is fulfilled by 93%.

Condensed Consolidated Statement of Financial Position		Group		Parent company
		31.12.2017	31.12.2016	31.12.2017	31.12.2016
		EUR '000	EUR '000	EUR '000	EUR '000
	ASSETS
NON-CURRENT ASSETS
Intangible assets		37 034	31 860	2 243	2 253
Property, plant and equipment		41 892	40 943	35 643	35 402
Investment properties		3 526	1 963	323	-
Financial assets		2 609	6 514	48 669	45 322
	TOTAL NON-CURRENT ASSETS	85 061	81 280	86 878	82 977
CURRENT ASSETS
Inventories		24 161	24 011	17 551	17 447
Receivables		34 049	36 124	31 586	32 531
Cash		3 158	3 165	1 989	2 163
	TOTAL CURRENT ASSETS	61 368	63 300	51 126	52 141
TOTAL ASSETS		146 429	144 580	138 004	135 118

	EQUITY AND LIABILITIES
EQUITY
Share capital		19 719	19 719	19 719	19 719
Share premium		2 504	2 504	2 504	2 504
Other components of equity		(74)	322	40	322
Retained earnings		75 675	74 081	73 268	73 012
Non-controlling interests		-	37	-	-
	TOTAL EQUITY	97 824	96 663	95 531	95 557
LIABILITIES
Non-current liabilities
Borrowings		15 878	18 800	14 805	17 777
Deferred corporate income tax		-	3 025	-	1 278
Deferred income		2 347	2 810	2 309	2 706
	Total Non-Current Liabilities	18 225	24 635	17 114	21 761
Current liabilities
Borrowings		14 013	7 020	13 247	6 362
Trade payables and other liabilities		15 892	15 769	11 714	11 039
Deferred income		475	493	398	399
	Total Current Liabilities	30 380	23 282	25 359	17 800
	TOTAL LIABILITIES	48 605	47 917	42 473	39 561
TOTAL EQUITY AND LIABILITIES		146 429	144 580	138 004	135 118

Consolidated statement of comprehensive income	Group		Parent company
	2017	2016	2017	2016
	EUR '000	EUR '000	EUR '000	EUR '000
Net revenue	122 076	110 693	91 713	91 096
Cost of goods sold	(47 231)	(40 855)	(30 441)	(29 678)
Gross Profit	74 845	69 838	61 272	61 418
Selling expense	(38 125)	(31 733)	(29 329)	(25 336)
Administrative expense	(23 653)	(19 735)	(20 170)	(18 020)
Other operating income	2 697	3 080	2 342	2 363
Other operating expense	(4 427)	(9 766)	(4 564)	(10 675)
Share of profit of an associate	113	63	-	-
Income from investments in subsidiaries	-	-	1 619	27
Financial income	236	3 479	299	3 355
Financial expense	(2 299)	(307)	(1 930)	(285)
Profit Before Tax	9 387	14 919	9 539	12 847
Corporate income tax	(1 977)	(2 883)	(1 547)	(2 564)
Deferred corporate income tax	3 379	(450)	1 278	(643)
PROFIT FOR THE REPORTING PERIOD	10 789	11 586	9 270	9 640
Other comprehensive loss for the reporting period	(114)	-	-	-
Total comprehensive income for the reporting period	10 675	11 586	9 270	9 640
Total comprehensive income attributable to:
The equity holders of the Parent Company	10 675	11 579	9 270	9 640
Non-controlling interests	-	7	-	-

Basic and diluted earnings per share, EUR	0.77	0.82	0.66	0.68

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with 45 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company's operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 50 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

Information prepared by:

Salvis Lapins

JSC Olainfarm

Member of the Management Board

Rupnicu iela 5, Olaine, Latvia, LV 2114

Phone: +371 6 7013 717

Fax: +371 6 7013 777

E-mail: Salvis.Lapins@olainfarm.lv

Pielikumi

OlainfarmZinojums_ENG.pdf (12300.91 kB)

Olainfarm_2017_Consolidated and Parent FS_ENG.pdf (3929.21 kB)